S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33

Rigel Pharmaceuticals (RIGL) Stock Forecast, Price & News

-0.07 (-3.74%)
(As of 05/26/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.73 million shs
Average Volume
1.85 million shs
Market Capitalization
$309.69 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Rigel Pharmaceuticals logo

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$149.24 million
Book Value
$0.04 per share


Net Income
$-17.91 million
Pretax Margin




Free Float
Market Cap
$309.69 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.06 out of 5 stars

Medical Sector

520th out of 1,424 stocks

Pharmaceutical Preparations Industry

230th out of 681 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

Is Rigel Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rigel Pharmaceuticals stock.
View analyst ratings for Rigel Pharmaceuticals
or view top-rated stocks.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Rigel Pharmaceuticals

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings data on Tuesday, May, 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.04. The biotechnology company earned $16.74 million during the quarter, compared to analyst estimates of $18.49 million. Rigel Pharmaceuticals had a negative trailing twelve-month return on equity of 219.06% and a negative net margin of 99.89%. During the same quarter in the previous year, the company posted $0.22 earnings per share.
View Rigel Pharmaceuticals' earnings history

What price target have analysts set for RIGL?

3 brokerages have issued 1-year price targets for Rigel Pharmaceuticals' shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Rigel Pharmaceuticals' stock price to reach $7.67 in the next year. This suggests a possible upside of 325.9% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rigel Pharmaceuticals' key executives?
Rigel Pharmaceuticals' management team includes the following people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 61, Pay $979.34k)
  • Mr. Dean L. Schorno CPA, Exec. VP & CFO (Age 59, Pay $623.46k)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 57, Pay $810.06k)
  • Dr. Wolfgang Dummer M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 56, Pay $644.05k)
  • Mr. David A. Santos, Exec. VP & Chief Commercial Officer (Age 59, Pay $600.64k)
  • Mr. Joseph Lasaga, Exec. VP of Corp. Devel. (Age 47)
  • Dr. Esteban S. Masuda, Exec. VP of Research (Age 60)
  • Mr. Tarek Sallam, VP of Marketing
What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals CEO Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among Rigel Pharmaceuticals' employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.63%), Vanguard Group Inc. (5.31%), State Street Corp (4.37%), Rock Springs Capital Management LP (2.86%), Lord Abbett & CO. LLC (2.56%) and Great Point Partners LLC (2.32%).
View institutional ownership trends for Rigel Pharmaceuticals

Which major investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Goldman Sachs Group Inc., State Street Corp, Great Point Partners LLC, Candriam Luxembourg S.C.A., Dimensional Fund Advisors LP, Rhenman & Partners Asset Management AB, and UBS Group AG.
View insider buying and selling activity for Rigel Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was acquired by a variety of institutional investors in the last quarter, including Woodline Partners LP, Assenagon Asset Management S.A., J. Goldman & Co LP, Walleye Capital LLC, Acadian Asset Management LLC, Graham Capital Management L.P., Renaissance Technologies LLC, and Vanguard Group Inc..
View insider buying and selling activity for Rigel Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $1.80.

How much money does Rigel Pharmaceuticals make?

Rigel Pharmaceuticals has a market capitalization of $309.69 million and generates $149.24 million in revenue each year. The biotechnology company earns $-17.91 million in net income (profit) each year or ($0.490010) on an earnings per share basis.

How many employees does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals employs 165 workers across the globe.

When was Rigel Pharmaceuticals founded?

Rigel Pharmaceuticals was founded in 1996.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is www.rigel.com.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 624-1100, via email at [email protected], or via fax at 650-624-1101.

This page was last updated on 5/27/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.